Calyxo, a Silicon Valley-based medical device company, pulled in a $40 million round of Series F funding. Ally Bridge Group and Janus Henderson Investors led the capital raise that enables Calyxo to further grow its CVAC System offering.
The company’s CVAC System is an FDA-cleared solution for minimally invasive kidney stone clearance. The platform leverages irrigation and vacuum aspiration to clear stone fragments during and after laser lithotripsy. Calyxo will invest its Series F in fueling the commercial expansion of this solution, clinical evidence generation and product innovation.
“More than 40,000 patients have now been treated with the CVAC System. Real-world experience, together with an established body of clinical evidence, indicates that the CVAC System is moving beyond early adoption and becoming an important part of the standard of care in kidney stone treatment,” Joe Catanese, Calyxo’s CEO, said in a statement. “This financing allows us to move faster in advancing our technology and expanding the evidence base to further improve patient care.”
